Non–Small Cell Lung Cancer (NSCLC) with Actionable Mutations

home / treatment-algorithms-with-the-oncology-brothers / non-small-cell-lung-cancer-nsclc-with-actionable-mutations

Balazs Halmos, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with non–small cell lung cancer with actionable mutations.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

EP. 1: Treatment Algorithm for NSCLC with Common Sensitizing EGFR Mutations

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS
July 18th 2024

Balazs Halmos, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with non–small cell lung cancer (NSCLC) with common sensitizing EGFR mutations.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

EP. 2: Approach to Treating Patients with NSCLC with Uncommon EGFR Mutations

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS
July 18th 2024

A thoracic medical oncologist provides insights on the treatment of patients with non–small cell lung cancer with uncommon EGFR mutations.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

EP. 3: Treatment Approach for NSCLC with ALK Mutations

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS
July 18th 2024

Medical oncologists discuss therapeutic practices for patients with non–small cell lung cancer with ALK mutations.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

EP. 4: Therapeutic Options for NSCLC with Rare Mutations

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS
July 18th 2024

The Oncology Brothers and Balazs Halmos, MD, provide clinical insights on therapeutic options for patients with NSCLC with rare mutations, including ROS1, BRAF V600E, and NTRK.

Balazs Halmos, MD, with the Oncology Brothers presenting slides

EP. 5: NSCLC Treatment: MET Exon 14 Skipping Mutations and RET Rearrangements

Rahul Gosain, MD;Rohit Gosain, MD;Balazs Halmos, MD, MS
July 18th 2024

Balazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.